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1. Introduction
Variants of gastric cancer account for approximately 5% of all carcinomas of the stomach. Some
variant carcinomas, such as lymphoepithelioma-like carcinoma, hepatoid carcinoma with or
without α-fetoprotein (AFP) production, small cell or neuroendocrine carcinoma, adenosqu‐
amous and squamous carcinoma, choriocarcinoma, sarcomatoid carcinoma, parietal cell or
oncocytic carcinoma, micropapillary carcinoma, mucoepidermoid carcinoma, chief cell
carcinoma, and Paneth cell carcinoma have been described, and recognition of the specific
subtype is important due to not only their correlation with a distinct clinical course and
prognosis but also differential diagnosis from metastasis from the outside of the stomach and
different therapeutic modalities, particularly in the era of targeted treatment. Gastric lym‐
phoepithelioma-like carcinoma and parietal cell or oncocytic carcinoma have been found to
have a lower risk of lymph node metastasis and better prognosis. However, other variants
such as hepatoid carcinoma, small cell or neuroendocrine carcinoma, adenosquamous and
squamous carcinoma, choriocarcinoma, sarcomatoid carcinoma, and micropapillary carcino‐
ma have shown to be associated with a poorer prognosis and a higher risk of metastasis to the
lymph node and other organs, compared to conventional intestinal or diffuse type of gastric
adenocarcinomas.
In recent years, early detection, endoscopic mucosal resection (EMR) for early gastric cancer,
and neoadjuvant therapy have made a remarkable progress in the management and prognosis
of gastric cancers. Thus, the prediction of aggressive behavior and accurate risk stratification
in the variants of gastric cancer has become more important than ever. The World Health
Organization (WHO) classification and the degree of differentiation have not been applied to
some variants of gastric carcinoma. Considering that EMR and neoadjuvant therapy are
selectively applied to patients with gastric carcinoma based on the tumor size, WHO classifi‐
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cation, and degree of differentiation, further specific subclassification for each variant should
be discussed to allow treatment to be directed to appropriate patient groups..
Recently, Giuffre et al analyzed the HER2 status in a cohort of rare histologic variants of
advanced gastric adenocarcinoma such as hepatoid adenocarcinoma and oncocytic adenocar‐
cinoma [1]. This series demonstrated that one of rare variants of gastric carcinoma, hepatoid
adenocarcinoma, has shown an increased HER2 overexpression in up to 42.86% of cases
compared to the intestinal (31.25%) and diffuse (3.45%) types of gastric adenocarcinoma.
Trastuzumab has been known as an additional useful therapeutic standard option for patients
with HER2-positive advanced gastric cancer. Therefore, this result and further studies may
bring a significant progress in clinical course and prognosis in patients with aggressive variants
of gastric carcinoma such as hepatoid adenocarcinoma. However, future studies are needed
to evaluate overexpression of HER2 in other variants of gastric carcinoma. The variants of
gastric carcinoma are listed in Table 1.
2. Epstein-Barr virus associated lymphoepithelioma-like carcinoma
Lymphoepithelioma-like carcinoma of the stomach (LELCS), also known as gastric carcinoma
with lymphoid stroma, undifferentiated carcinoma with lymphoid stroma or medullary
carcinoma, is a unique variant of gastric adenocarcinoma which is highly associated with
Epstein-Barr virus (EBV) infection. This variant was described originally by Watanabe et al in
1976 and accounts for approximately 4% of all gastric carcinomas [2-4]. It has recently been
emphasized that the role of EBV infection in the carcinogenesis of LELCS. The incidence of
EBV-associated gastric adenocarcinoma varies from 1.3% to 20.1% in different areas, with an
average of 10% worldwide [5, 6]. The prevalence of EBV infection has been found approxi‐
mately 75 % of LELCS and 16% of conventional gastric adenocarcinoma in North America by
EBV-encoded ribonucleic acids in situ hybridization (EBER-ISH) [7].
The clinicopathologic and molecular characteristics of EBV-associated LELCSs are quite
different from those of conventional gastric carcinoma, such as a male predominance (male to
female ratio: 2-3.4:1), predisposition to proximal stomach, frequent association with multiple
and remnant gastric cancers, a lower frequency of lymph node metastasis, a relatively
favorable prognosis, and aberrant concordant methylation of multiple genes [4, 8-10]. The
mean age of diagnosis is 54.8 years, younger than conventional gastric carcinomas [11]. The
clinical symptoms of LELCS are similar with conventional gastric adenocarcinoma, and
patients with EBV-associated gastric carcinoma are known for elevated antibodies against
EBV-related antigens. Levine et al reported that patients with EBV-associated gastric carcino‐
ma have significantly high IgG and IgA antibody titer to EBV viral capsid antigen more than
5 years preceding their first diagnoses [12].
Watanabe and Yanai et al had reported the specific endoscopic findings of EBV-related LELCs
in early and advanced lesions [4, 8]. In their series, approximately 80 % of LELCS appear to be
a superficial depressed type, such as IIc, IIc+III, and IIa+IIc, frequently combined with ulcer in
an early stage. Endoscopic ultrasonography of this variant demonstrates a hypoechoic
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Histologic type Incidence Mean age Sex Clinical importance Morphologic feature Prognosis 
 
EBV-associated 
lymphoepithelioma-like 
carcinoma 
 
 
4% 
 
54.8 yrs 
 
M:F= 2-3.4:1 
 
Possible good candidate for EMR 
and DNA methyltransferase 
inhibitor 
 
Undifferentiated tumor cells embedded within a 
lymphoid stroma 
 
Better prognosis 
compared to CoA (5-
YSR: 71.4%) 
 
 
Hepatoid adenocarcinoma 
 
0.4-0.7% 
 
64.5 yrs 
 
M:F=3.5:1 
 
Possible good candidate for anti-
HER2 therapy (HER2 
overexpression) 
 
 
Tumor showing hepatoid differentiation with an 
immunoreactivity of AFP and glycan3 
 
Worse prognosis 
compared to CoA (5-
YSR: 9%) 
 
Neuroendocrine cell 
carcinoma 
 
0.1-0.6% 
 
65 yrs 
 
M:F=2.9:1 
 
Response well to chemotherapy 
 
Monotonous polygonal cells having fine 
granular chromatin and inconspicuous nucleoli 
with an immunoreactivity of neuroendocrine 
markers 
 
 
Unfavorable prognosis 
(median survival: 1.7 
years) 
 
Squamous and 
adenosquamous carcinoma  
 
0.04-0.9% 
 
64 yrs 
 
M:F=5:1 
 
Differentiation from squamous or 
adenosquamous cell carcinoma 
arising from distal esophagus  
 
Tumors with definite squamous differentiation 
including keratinization, squamous pearl 
formation, and intercellular bridges with or 
without a glandular component 
 
 
Unfavorable prognosis 
(mean survival: 1.6 
years) 
 
Choriocarcinoma 
 
0.08% 
 
58.6 yrs 
 
M:F=2.3:1 
 Elevated serum β-HCG 
Frequent cause of gastrointestinal 
bleeding and some hormone effects  
  
 
Tumor with an admixture of cytotrophoblasts 
and syncytiotrophoblasts 
 
Unfavorable  prognosis 
(maximum survival: one 
year) 
 
 
Sarcomatoid carcinoma 
 
50 cases 
reported 
 
 
45 yrs 
 
M:F=2.3:1 
 
Diagnosed at an advance stage with 
lymph node and liver metastasis 
 
 
Tumor with a high grade sarcomatous 
component   
 
 
Unfavorable prognosis 
(mean survival: 10 
months) 
 
 
Acinar cell carcinoma 
 
10 cases 
reported 
 
64.8 yrs 
 
M:F=1:1 
 
Tumor arising from pancreatic 
heterotopias or de novo acinar 
metaplasia 
 
 
Tumor with acinar cell differentiation and 
pancreatic exocrine enzyme production 
confirmed by immunohistochemistry 
 
Undetermined 
 
Invasive micropapillary 
carcinoma 
 
0.07% 
 
66.2 yrs 
 
M:F=2.5-3:1 
 
High incidence of lymphovascular 
invasion and lymph node metastasis 
 
Tumor with papillary clusters devoid of 
fibrovascular cores within lacunar spaces 
 
Worse prognosis 
compared to CoA  
(5-YSR:30%) 
 
 
Gastric adenocarcinoma of 
fundic gland type (chief cell 
predominant) 
 
A few cases 
reported 
 
65 yrs 
 
M:F=1:1 
 
Differentiation from a fundic gland 
polyp 
 
Well differentiated adenocarcinoma admixed 
with predominantly chief cells and scattered 
parietal cells 
 
 
Favorable prognosis 
expected but limited data 
 
Parietal cell carcinoma and 
oncocytic carcinoma 
 
Less than 30 
cases 
reported 
 
 
70.2 yrs 
 
M:F=9:1 
 
Occurs in an older population with a 
favorable prognosis 
 
Tumors showing parietal cell differentiation with 
or without an immunoreactivity of H+/K+ 
ATPase 
 
Favorable prognosis but 
limited data 
M:F indicates male to female ratio; EMR: endoscopic mucosal resection; CoA: conventional adenocarcinoma; AFP: Alpha-fetoprotein; 5-YSR: 5-
M:F indicates male to female ratio; EMR: endoscopic mucosal resection; CA: conventional adenocarcinoma; AFP: Alpha-
fetoprotein; 5-YSR: 5-year survival rate
Table 1. Variants of Gastric carcinoma
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submucosal tumor-like protrusion with a large thickness compared to the length in an early
lesion. Most LELCSs appear as a fungating mass (Bormann type II) accompanied by marked
thickening of the gastric wall in an advanced stage (Fig. 1).
Figure 1. Gross photograph of EBV-associated lymphoepithelioma-like carcinoma in an advance stage. This tumor
usually presents as a fungating mass (Bormann type II).
Histologically, LELCS has a well demarcated and pushing border and nests of poorly or
undifferentiated tumor cells embedded within a lymphoid stroma. The tumor cells are
arranged in syncytia, microalveolar, thin trabecular, or primitive tubular patterns. Also, they
contain vesicular to clear nuclei, prominent nucleoli, and abundant eosinophilic polygonal
cytoplasm with poorly defined cell borders (Fig 2). Generally, tumor cells grow in a diffuse
manner intermixed with lymphocytes and plasma cells, mimicking malignant lymphoma
(Schmincke type). However, a sharp demarcation between the tumor nests and lymphocyte
stroma that is composed of variable amounts of lymphocytic infiltration, sometimes with
lymphoid follicles, is noted (Regaud type) but no desmoplastic reaction is identified. Rarely,
giant cells and epithelioid granulomas are observed within the lymphoid stroma [13, 14]. In
the early lesion, LELCS shows a “lace pattern”, which consists of columnar arrangement and
intercolumnar fusion of neoplastic glands between dense lymphocytic infiltration at the
intermediate zone of lamina propria [15]. This tumor is usually accompanied with severe
atrophic gastritis in the background but not associated with intestinal metaplasia or Helico‐
bacter pylori infection that are often observed in usual gastric adenocarcinoma [16].
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Figure 2. High magnification view of LELCS shows syncytial and solid nests of undifferentiated tumor cells with vesicu‐
lar nuclei and prominent nucleoli surrounded by dense lymphocytic infiltration on H&E stain
The epithelial cell component of this variant is positive for keratins. Also HLA-DR expression
of tumor cells associated with dense lymphocytic infiltrates can be detected in some cases of
EBV-associated LELCS [17]. Increased dendritic cells within a lymphocyte stroma are also seen,
which are positive for S100 and CD83. CD8+ T lymphocytes are the predominant cells
infiltrating into tumor cell nests in EBV-associated LELCS, many of which express perforin
and granzyme B [18]. Florid proliferation of CD8+ T lymphocytes within tumor cells seems to
be associated with the host immune response to remove EBV antigen or cellular EBV-induced
antigen [19].
EBV has specific latency expression patterns in different EBV-associated malignancies. EBV-
associated LELCS can express viral latent genes and related products, not only EBV-encoded
small ribonucleic acids (EBER) but also EBV-determined nuclear antigen type 1, BamHI A
region rightward transcripts, and variable latent membrane protein 2A and 2B [20]. Polymer‐
ase chain reaction (PCR) to amplify EBV deoxyribonucleic acid fragments and EBER-ISH
techniques could be used to detect EBV in tumor tissues; however, as a PCR test for amplifying
EBV DNA is very sensitive and may cause a false positivity, and EBERs are always abundantly
expressed in nearly 100% of tumor cell tissues (Fig.3), EBER-ISH technique is a gold standard
test to detect EBV in paraffin-embedded tissues [21].
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Figure 3. Microscope and EBER-ISH photographs of EBV-associated lymphoepithelioma-like carcinoma. A. A relatively
well circumscribed mass with focal infiltration into subserosa. Reactive lymphoid follicles are scattered between tumor
nests combined with dense lymphocytic infiltration. B. EBER-ISH highlights solid nests of EBV-infected tumor cells with
cytoplasmic staining pattern in lymphoepithelioma-like carcinoma.
Previous studies of conventional gastric adenocarcinoma have been shown 34-60% of p53
overexpression. Some studies showed the frequency of p53 immunoreactivity, approximately
14%, was much lower in patients with EBV-associated LELCS compared to conventional
gastric carcinoma [22]. However, other studies have almost same frequency of p53 expression
with conventional gastric adenocarcinoma [23, 24]. The role of p53 mutation in the develop‐
ment of EBV-associated gastric carcinoma is still unclear.
If an accompanying lymphoid stroma contains multiple reactive follicles and intense lympho‐
cytic infiltration in LELCS can be mistaken as a pseudolymphoma or lymphoma. It is important
to examine the presence of malignant epithelial cell component carefully. Immunohistochem‐
ical markers for the cytokeratins, AE1/AE3 and CAM5.2, should be essential to detect in which
only scarce undifferentiated malignant epithelial cells are present.
EBV  is  a  ubiquitous  γ-1  herpes  virus  usually  acquired  during  childhood  via  salivary
transmission,  which establishes  a  life-long persistent  infection of  B  cells  in  over  90% of
adults [20]. EBV has been linked to the pathogenesis of several mesenchymal and epithe‐
lial  neoplasms  including  nasopharyngeal  carcinoma,  B  and  T  cell  lymphomas,  NK  cell
malignancies,  and  a  subset  of  smooth  muscle  tumors  [25].  The  role  of  EBV  in  gastric
carcinoma is considered to be directly oncogenic, but is still largely unknown. The infection
of EBV is assumed to be occurred in the very early stage of carcinogenesis [23]. Howev‐
er,  there is  still  a  controversy over whether EBV infects gastric  epithelial  cells  before or
after the development of invasive gastric carcinoma [9].
Studies for genetic abnormality for EBV-associated gastric carcinoma are still limited and
sparse. Several previous studies had failed to demonstrate any significant chromosomal loss
or gain in comparative genome hybridization, changes of DNA copy number and microsa‐
tellite clearly. In contrast to inconsistent and negative results in genetic alteration, epigenet‐
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ic  alterations such as promoter hypermethylation,  which bring in chromatin remodeling
and  silencing  of  tumor-related  genes,  plays  a  key  role  in  the  carcinogenesis  of  EBV-
associated gastric carcinoma [26].  Kusano et al  demonstrated that EBV-associated gastric
carcinomas  were  strongly  associated  with  high  CpG-island  methylation  (CpG-island
methylator  phenotype-  high,  CIMP-H)  by  using  methylation-specific  polymerase  chain
method [27]. Other epigenetic series about EBV-associated gastric carcinoma have shown
simultaneous methylation of multiple genes, including cell cycle regulation (p14, p15, p16,
and  cox2),  DNA  repair  and  protection  (HMLH1,  MGMT,GSTP1),  cell  adherence  and
metastasis (E-cadherin, TIMP3), angiogenesis (THBS1), apoptosis (DAP-kinase, bcl-2, p73),
and signal transduction (APC, PTEN, RASSF1A) [28, 29]. Higher frequencies of hyperme‐
thylation of cancer-related genes found in EBV-associated gastric carcinoma suggest a close
relationship  between  EBV  infection  and  aberrant  methylation  of  this  variant  during  its
carcinogenesis. Also, these findings suggest that DNA methyltransferase inhibitors such as
5-aza-2΄-deoxycytidine  (5-aza-CdR)  or  trichostatin  A  (TSA),  which  can  induce  the  lytic
phase  of  EBV  infection  in  EBV  positive  gastric  cancer  cell  lines,  can  be  a  promising
therapeutic agent specially for EBV-associated gastric carcinoma [30].
Another interesting characteristic of EBV-associated gastric carcinoma is its higher occurrence
among gastric remnant carcinomas, ranging from 27% to 42% [31-33]. Chen et al hypothesizes
that the injuries of gastric mucosa and/or changes of the microenvironment within the remnant
stomach may be involved in the development of EBV-associated gastric carcinoma [34].
EBV-associated LELCS has known to have a low risk of lymph node metastasis [35]. Interest‐
ingly, whether the presence of tumor metastasis within the regional lymph nodes or not,
perigastric lymph nodes frequently show reactive hyperplasia that represents a host immune
response against LELCS [4]. EBV-associated LELCS shows a very low rate of regional lymph
node metastasis especially if the tumor involves in the mucosa and submucosa as an early
gastric cancer [4]. The patients with this variant tumor can be good candidates for EMR in
regard to a lower frequency of lymph node metastasis and a relative well circumscribed tumor
margin that can be easily assessed endoscopically. Some clinical trials to remove EBV-
associated LELCS in an early stage have been reported using an endoscopic resection such as
EMR or submucosal dissection [36, 37]. The patients treated with endoscopic resection have
shown a benign clinical course without recurrence or metastasis. The prognosis of EBV-
associated gastric carcinoma has been considered better than conventional gastric carcinoma.
Song et al reported that 5-year overall survival rate of EBV-associated gastric carcinoma was
71.4%, and disease-free survival rate was 67.5% compared to 56.1% and 55.2% of those usual
gastric carcinoma and suggested the prognosis of EBV-associated gastric carcinoma depends
on the patient’s inflammatory response (tumor-infiltrating lymphocyte counts) [11].
3. Hepatoid adenocarcinoma
Hepatoid adenocarcinoma of the stomach (HACS) was first described by Ishikura et al in 1985
as a subtype of AFP producing gastric carcinoma, which has a histologic similarity with
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hepatocellular carcinoma and distinct clinicopathological properties [38]. The incidence of this
variant ranges from 0.38% to 0.73% of all gastric cancer [39, 40]. The mean age of diagnosis is
64.5 years (range from 49 to 78 years), similar to that of conventional gastric carcinomas. The
clinical symptoms are similar to those seen in patients with conventional gastric adenocarci‐
noma except marked elevated serum level of AFP in most patients. Characteristically, earlier
studies demonstrated that HACS frequently combined with vascular invasion, liver metasta‐
sis, and a higher incidence of lymph node metastasis which result in a poorer prognosis than
other common types of gastric adenocarcinoma [41, 42].
AFP is a serum protein produced by fetal liver, yolk sac cells, and some fetal gastrointestinal
cells [43]. HACS is characterized by distinct hepatoid differentiation histologically and the
production of liver specific proteins including AFP confirmed by immunohistochemistry.
However, not all HACSs produce hepatic specific protein. Approximately 54 % of HACSs
express AFP by immunohistochemistry and 63% of patients with HACS show an elevated
serum AFP level [39, 44]. In addition, there are some histologic types of carcinoma other than
HACS, tubular/papillary adenocarcinomas, poorly differentiated medullary carcinoma, and
enteroblastic adenocarcinoma, also can produce and secrete AFP [38, 45-48].
The most commonly found macroscopic type of HACS is 0-IIc (superficial depressed type) in
an early lesion [49]. This tumor can occur as a circumscribed mass, Bormann type II (fungating
type) or III (ulceroinfiltrative type) as an advanced cancer in the antrum and lower body of
the stomach (Fig.4) [44, 49]. Microscopically, this variant contains areas of hepatoid differen‐
tiation showing structural mimicry of liver tissue such as sheet-like or trabecular arrangement
of tumor cells with sinusoid-like vasculature and bile canaliculus-like structure [50]. This
tumor consists of cuboidal or polygonal cells with centrally located nuclei and abundant
eosinophilic cytoplasm (Fig.5). However, there is no consensus for quantification of the
proportion of hepatocellular differentiated component yet to accept as HACS. The proportion
of hepatoid component ranges from 10 to 90% in reported cases of HACS [51]. The glandular
component such as well-differentiated tubular or papillary adenocarcinoma frequently
intermingles with the hepatoid component. The transition between glandular and hepatoid
components of HACS can be gradual or abrupt. Occasionally, bile and periodic acid-Schiff-
positive/diastase-resistant hyaline globules may be observed in intracellular and extracellular
sites. In addition to the production of liver-specific proteins such as AFP as well as prealbumin,
albumin, and transferrin, Proteins Induced by Vitamin K Absence - II (PIVKA-II) and Hep-
par1 antigen can be detected in tumor cells [38, 52, 53]. Some HACSs exhibit extensive
lymphovascular invasion, extending to veins with tumor emboli, which results in early
metastasize to other organs, predominantly to the liver [39].
Immunohistochemically, the tumor cells are positive for CK8, CK18, CK19, CK20, but negative
for CK7. Also this variant can express the canalicular pattern of polyclonal carcioembryonic
antigen (CEA), α-1 antitrypsin, and α-1 antichymotrypsin [54]. The immunoreactivity of
PIVKA-II and Hep-par1 are variably observed. Glypican-3 is a cell surface heparin sulfate
proteoglycan considered to be an oncofetal protein because of its presence in fetal liver and
liver tumors (hepatocellular cell carcinoma and hepatoblastoma) [55]. The immunohistochem‐
ical staining pattern of glypican-3 is strongly positive in membrane and cytoplasm of hepatoid
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tumor cells (Fig. 5). Hishinuma et al reported that glypican 3 is more sensitive (100% sensitivity)
than either Hep-par1 or AFP but Hep-par1 is more specific as an immunohistochemical marker
for HACS [51]. In a series by Kinjo et al showed that AFP has 81.1% of sensitivity and 46.1%
of specificity and glypican-3 has 90.5% of sensitivity and 63.2% of specificity [49]. These studies
support both AFP and glypican-3 could be useful markers to make a diagnosis of HACS.
Many cytogenetic and molecular studies had been undertaken to investigate pathogenesis and
biological behavior of this variant. However, the histogenesis of HACS is still unclear.
Kishimoto et al proposed that gastric carcinoma might acquire hepatic differentiation during
the tumor progression, “HACS transdifferentiation”[56]. Akiyama et al demonstrated that the
hepatoid component exhibited exactly same patterns of chromosome X inactivation, p53 gene
mutation, the level of p53 expression, and loss of heterozygosity with conventional adenocar‐
cinomatous component of HACS [57]. These findings suggest a monoclonal origin of both
glandular and hepatoid elements of HACS and support “HACS transdifferentiation” as the
most accepted histogenesis.
Differential diagnoses of HACS include other similar-appearing tumors (lung, pancreas,
esophagus so on) and hepatocellular cell carcinoma. Particularly, the metastatic HACS to the
liver may be almost indistinguishable from hepatocellular cell carcinoma due to overlapping
clinicopathologic features such as elevated AFP level, hepatoid morphology, and immunoex‐
pressions of AFP, polyclonal CEA, and alpha-1 antitrypsin. Moreover, the hepatoid component
of HACS can be more prominent in metastatic lesions to perigastric lymph nodes or liver [45,
58]. The presence of underlying disease such as liver cirrhosis and the presence of primary
Figure 4. Gross photograph of hepatoid adenocarcinoma. The tumor presents as a fungating mass (Bormann type II)
in the lower body of the stomach which projects exophytically into the abdominal cavity. The subserosal lesion shows
extensive necrosis and hemorrhage on the cut surface.
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lesion detected by screening modalities such as endoscopy and abdominal computerized
tomography scan would be useful to differentiate metastatic HACS and primary hepatocel‐
lular cell carcinoma. Although hepatocellular cell carcinoma arising in non-cirrhotic liver and
without known risk factors is rare, this tumor has been reported to appear as a single nodule
with pseudo-adenomatous or sclerosing pattern histologically [59, 60].
In  recent  clinical  series  by  Baek  et  al,  approximately  77%  of  patients  with  HACS  at
presentation were  diagnosed as  an advanced stage,  stage III  or  IV [44].  Median overall
survival  and progression free  survival  of  these  patients  after  gastrectomy and/or  pallia‐
tive  chemotherapy  were  8.03  months  (95%  CI:  6.59-9.47)  and  3.47  months  (95%  CI:
0.65-6.29),  respectively.  The incidence of liver metastasis of HACS is significantly higher
than that of conventional gastric adenocarcinoma. Liu et al reported the overall incidence
of liver metastasis was 75.6% including 8.9% synchronous and 73.2% metachronous liver
metastasis in HACSs compared to 11.6 %, including 1.8% synchronous and 9.9% metachro‐
nous  liver  metastasis  in  conventional  gastric  adenocarcinoma  [50].  The  overall  5-year
survival rate of HACS was 9% compared to 44% in conventional gastric adenocarcinoma
[50].  Most of HACS cases clinically appear to chemoresistant and curative resections are
limited due to advanced lesions at  diagnosis.  Kamata et  al  demonstrated multiple ATP-
binding  cassette  transporters  related  with  multidrug resistance  of  tumor  such  as  multi‐
drug resistant-associated proteins 1,2, and 6 were expressed frequently in HACS [61]. This
finding suggested that ATP-binding cassette transporters participated in the mechanism of
multidrug resistance in HACS.
HER2 gene amplification and protein overexpression have been introduced as the target
therapy with anti-HER2 humanized monoclonal antibody (trastuzumab) in various cancers
including gastric cancer in an advance stage. Although reported rates of HER2 overexpres‐
Figure 5. Microscopic photograph of hepatoadenocarcinoma and its immunostaining pattern of glycan-3. A. Solid
nests of tumor cells are incompletely surrounded by sinusoid-like microvascular structure. This tumor is composed of
polygonal cells with centrally located polymorphic nuclei and pale pinkish relatively abundant cytoplasm, resembling
hepatocytes. B. The glycan-3 immunostain shows membranous and cytoplasmic staining pattern of tumor cells.
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sion  have  been  variable,  it  accounts  for  approximately  20  %  of  all  gastric  carcinomas.
Recently, Giuffre et al reported that a markedly increased HER2 amplification was more
frequent in HACS (42.9%) than that seen in tubular gastric adenocarcinomas (31.3%) [1].
This finding shows trastuzumab can be a useful therapeutic standard option not only for
patients with advanced gastric cancer but also in aggressive variants like HACS.
4. Neuroendocrine cell carcinoma
Primary small cell carcinoma of the stomach (PSCCS) is an exceedingly aggressive variant
of gastric carcinoma with neuroendocrine differentiation. Since Matsusaka et al described
this variant first in 1976, less than 230 cases have been reported in the literature [62]. This
tumor  also  has  been  referred  to  “oat  cell  carcinoma”  and  “atypical  carcinoid”  and  ac‐
counts for 0.1 - 0.6% of total gastric cancers [63, 64]. The mean age of presentation is 65
years (range, 42 to 84 years) and it commonly affects males [65]. The clinical presentation
is  similar  to  those  seen  in  patients  with  conventional  gastric  adenocarcinoma  in  an
advanced stage.  PSCCS may rarely  secrete  hormones  such as  vasoactive  intestinal  pep‐
tide,  neuron-specific  enolase,  pro-gastrin-releasing  peptide,  antidiuretic  hormone,  and
adrenocorticotropic  hormone  [66-68].  A  few  cases  of  PSCCS  have  been  reported  in
association  with  paraneoplastic  syndromes  including  paraneoplastic  neurological  syn‐
drome and Cushing syndrome by ectopic production of ACTH [69, 70].
PSCCS tends to metastasize early to regional lymph nodes and liver and extends to surround‐
ing organs including liver, transverse colon, pancreas, and diaphragm at the presentation
[71-74]. In the largest retrospective series, Chiba et al demonstrated that PSCCSs have a higher
incidence rate of lymphatic invasion (88.9% vs. 56.6%), vascular invasion (75.6% vs. 31.6%),
and lymph node metastasis (82.1% vs. 58.8%) compared to those of conventional gastric
carcinoma [75].
Neuroendocrine cell carcinomas of the gastrointestinal tract are usually responded well to
the  chemotherapy.  Although  there  has  been  no  established  chemotherapy  regimen  for
PSCCS due to its rarity, generally it has been recognized that surgical resection alone may
not  be  sufficient  treatment  and  emphasize  the  importance  of  adjuvant  chemotherapy,
especially for advanced disease. Fukuda et al insisted that intensive chemotherapy with or
without  surgical  resection  should  be  recommended  for  this  tumor  at  any  stage  [76].
Recently,  some studies  have  reported  good response  of  some chemoregimens  routinely
used for lung SCC such as etoposide/cisplatin, irinotecan/cisplatin, and S1/cisplatin [65, 68,
77, 78]. The 5-year survival rate of patients with gastric neuroendocrine carcinoma has been
reported  to  be  22.1%-  43.8%  and  the  median  survival  time  is  19  month  [68,  79,  80].
However,  long-term  survival  up  to  3  years  was  reported  in  a  patient  with  aggressive
adjuvant chemotherapy [68].
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Figure 6. Gross and microscopic photographs of neuroendocrine carcinoma in the stomach. A. It forms an ulceroinfil‐
trative solid mass (Bormann type III) in the upper body of the stomach. B. At lower magnification, this solid tumor
invades into the subserosa. C. Dark purple solid nests of poorly differentiated neuroendocrine carcinoma invades into
the muscularis mucosa accompanied by desmoplastic reaction in the surrounding tissue.
Macroscopically, the average size of the tumor is approximately 6.3 cm [65]. This tumor is an
ulcerative or protruding mass (70% of cases) with frequent invasion to subserosa (Fig.6) [65,
81]. PSCCS can be classified as pure (Fig.7) or mixed (composite) SCC (Fig.8) depending on
the proportion of neuroendocrine cell component. However, regardless of the proportion of
neuroendocrine carcinoma in total volume of gastric carcinoma, its presence has been corre‐
lated with a poor prognosis. Approximately 60% of PSCCS cases are associated with conven‐
tional gastric adenocarcinoma, and rare cases with sarcomatoid carcinoma, adenosquamous,
and squamous carcinoma variants have been reported [82-85]. Histologically, diagnostic
criteria for PSCCS are identical with those for pulmonary neuroendocrine tumors by the WHO/
International association for the Study of Lung Cancer [86]. First of all, the SCC histology is
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defined as having a markedly high nuclear/cytoplasmic ratio and hyperchromatic small nuclei
(less than 3 resting lymphocytes) with finely granular chromatin and inconspicuous or rarely
conspicuous nucleoli. Frequent nuclear molding might be present. Focal or extensive necrosis
can be seen. The typical organoid architecture pattern of low grade neuroendocrine neoplasm
(eg. carcinoid) is rarely present in PSCCS. As a high grade tumor, their proliferative rate is
high, and all exhibit more than 10 mitoses per 10 high power fields, with a mean of 40 to 50
mitoses [87]. Intestinal metaplasia may be seen in the background of gastric mucosa. In cases
with classic histologic features of neuroendocrine tumors, positive staining for neuroendocrine
markers is not a requirement for a diagnosis [87].
The pathogenesis of neuroendocrine carcinoma of the stomach is unknown. The most com‐
monly accepted hypothesis is the presence of a “pluripotent stem cell” that has a potential to
grow and differentiate into other cell types producing mucin or keratin [88]. This hypothesis
has been supported by some cases of composite neuroendocrine carcinomas with other
glandular or squamous cell components [89, 90]. Other suggested theory is that neuroendo‐
crine carcinoma of the stomach arises from neuroendocrine precursor cells in gastric adeno‐
carcinoma during its genetic progression [91].
Since  PSCCS could be  occasionally  misdiagnosed as  poorly  differentiated adenocarcino‐
ma  or  malignant  lymphoma  due  to  accompanying  crush  artifact  in  small  biopsies,
Grimelius stain and immunohistochemistry would be useful to differentiate morphologic
mimickers. Immunohistochemical staining for neuroendocrine markers, including chromog‐
ranin,  synaptophysin,  and CD56, is  usually positive (Fig.9)  [81,  92,  93].  Its  intensity and
distribution  can  vary,  with  most  examples  showing  patchy  and  moderately  intense
immunoreactivity. Also, most PSCCSs show an immunoreactivity for keratin AE1/AE3 and
CEA but not for high molecular cytokeratin CK34βE [87]. Recently, Li et al demonstrated
the low molecular  weight  cytokeratin,  CK8 (CAM 5.2),  is  more commonly expressed in
SCC  in  gastrointestinal  tract  including  PSCCS  than  is  the  expression  of  AE1/AE3  or
epithelial  membrane  antigen,  suggesting  CK8  as  a  sensitive  marker  for  SCCs  of  the
gastrointestinal tract [94]. The proliferation index for Ki-67 is high, usually more than 25
% positive nuclei. Rindi et al have reported that angioinvasion, tumor size, clinicopatholog‐
ical type, mitotic count, and Ki-67 proliferation index are predictors of tumor malignancy
and patient outcome in neuroendocrine tumors of the stomach [79].
At the current time, neuroendocrine carcinomas in the gastrointestinal tract are classified
into neuroendocrine carcinoma (small and large cell subtypes) and mixed adenoneuroendo‐
crine  carcinoma  by  World  Health  Organization  (WHO)  [95].  Large  cell  neuroendocrine
carcinoma of the stomach (LCNECS) is  defined as a high grade or poorly differentiated
malignant neuroendocrine tumor of non-small cell type. In the largest series by Jiang et al,
LCNECSs account for at least 1.5% of all gastric cancer [96]. In this series, the mean age
of  the  patients  with LCNECS is  62.7  years  (range,  47  to  79  years)  and it  mostly  affects
males.
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Figure 7. Pure well differentiated neuroendocrine carcinoma of the stomach. A. Well differentiated neuroendocrine
carcinoma shows a typical organoid or solid nest growth pattern. B. At higher magnification, the tumor cells display
characteristic cytologic features of neuroendocrine cells including hyperchromatic small nuclei with finely granular
chromatin (“salt and pepper” nuclei) and inconspicuous nucleoli.
Figure 8. Mixed small cell carcinoma reveals an admixture of poorly differentiated adenocarcinoma with signet ring
cell features and small cell carcinoma. A. In a small biopsy, neuroendocrine carcinoma component can be misled as a
part of poorly differentiated adenocarcinoma. B. At high magnification, the upper part of this picture shows rounded
aggregates of signet ring cell carcinoma with mucin. Adjacent to signet ring cell carcinoma, solid nests of poorly differ‐
entiated neuroendocrine tumor cells with a high nuclear to cytoplasmic ratio are present in the lower part of this pic‐
ture.
Grossly, the mean size of the tumor is 6.4 cm (range 1.1 to 13.0 cm) and 66% of cases are
Bormann type II or III in an advanced stage [96]. The diagnostic criteria for LCNECS is defined
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as having the following features: a diffuse growth pattern or “neuroendocrine architecture”
(organoid, nesting, palisading, rosettes, or trabeculae), monotonous polygonal or round to oval
cells with moderate amounts of slightly eosinophilic cytoplasm and ill defined cell border,
granular or vesicular nuclei with evenly distributed granular chromatin, and with or without
visible nucleoli [97]. Focal lumen formation or focal intracytoplasmic mucin might be seen,
and are not feature for exclusion. LCNECSs usually combine with other common adenocar‐
cinoma components. Immunohistochemical evidence of neuroendocrine differentiation is
defined as positive staining for one of three neuroendocrine markers, chromogranin, synap‐
tophysin, and CD56, in > 20% of the tumor cells [97]. In a relatively large study to compare
LCNECS and PSCCS by Matsui et al, they demonstrated LCNECSs reveal a higher mitotic
count, larger polygonal cells, a lower nuclear-cytoplasmic ratio, coarser nuclear chromatin,
and more frequent conspicuous nucleoli than PSCCSs [81].
The main difficulty with the diagnosis of gastric neuroendocrine carcinoma is to distinguish
them from poorly differentiated adenocarcinoma with solid growth pattern and malignant
lymphoma. Preoperative diagnosis of neuroendocrine carcinoma from gastric endoscopic
biopsy specimens would be challenging for the pathologists due to its histologic heterogeneity
as well as the propensity of neuroendocrine tumor that mainly proliferates under the mucosal
layer [65, 71]. Also, neuroendocrine carcinoma of the stomach cannot be easily recognizable
due to less prominent neuroendocrine histologic features in high grade tumor cells. These
factors can result in limited and demanding biopsy specimens for making a diagnosis of PSCCS
preoperatively. However, careful evaluation for hidden or faint neuroendocrine architecture,
cytologic features of neuroendocrine cells, and comparable immunohistochemical profiles
would be useful to differentiate two disease entities. Sometimes ultrastructural study can help
to demonstrate accumulation of electron-dense core neurosecretory granules measuring 200
nm in diameter in these tumors [98].
Primary gastric malignant lymphoma can be distinguished by immunoreactivity of CD45 and
lack of cytokeratins. SCC of the lung metastatic to the stomach should always be considered
in the differential diagnosis of PSCCS. With limited data, staining for the lung marker, thyroid
transcription factor-1 (TTF1), seems to be almost always negative in neuroendocrine tumors
of the gastrointestinal tract [99]. So TTF1 can be helpful to differentiate a metastatic lesion from
SCC of the lung.
Another  subtype  of  neuroendocrine  carcinoma  is  a  mixed  neuroendocrine  carcinoma.
Although  localized  endocrine  cell  differentiation  in  benign  or  malignant  glandular
neoplasm of the gastrointestinal tract is  relatively common, truly mixed glandular-endo‐
crine neoplasms (adenoneuroendocrine carcinoma) are rare.  These tumors are composed
of both glandular component like conventional adenocarcinoma and recognizable neuroen‐
docrine component of small or large cell type that comprises substantial proportions of the
tumor  volume  with  each  component  at  least  30%  of  the  lesion  [100].  Most  of  mixed
glandular-neuroendocrine neoplasms of the stomach are malignant tumors arising in the
background of atrophic gastritis.
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Figure 9. A. Small cell carcinoma of stomach forms solid nests or sheets of tumor cells that invades into the gastric
mucosa. B. This variant shows a strong positivity for one of neuroendocrine markers, chromogranin.
5. Squamous and adenosquamous carcinoma
Primary squamous and adenosquamous carcinoma of the stomach is an extremely rare and
aggressive variant of the stomach cancer that accounts for 0.04 to 0.9 % of all gastric carcinoma
[101, 102]. Although clinical manifestation of the patients with primary squamous and
adenosquamous carcinoma of the stomach is similar with patients with conventional gastric
adenocarcinoma, it has been reported a mildly elevated serum level of squamous cell carci‐
noma antigen and a long history of smoking and alcohol abuse in some patients [103-105]. The
mean age of presentation is 64 years (range, 17 to 89 years) and men are affected about five
times as often as women [104]. Patients with primary squamous or adenosquamous carcinoma
of the stomach frequently present with advanced stage disease (pT3 or T4) with or without
metastases or involvement of other organs (stage III or IV) [106]. It has known that these
variants do not response well to the routine chemoregimen for conventional gastric carcinoma.
There is no established standard adjuvant chemoradiation therapy for patients with primary
squamous and adenosquamous carcinoma in the stomach. However, one isolated case
suggested that low-dose 5-fluorouracil plus cisplatin would be an effective preoperative
chemoregimen to shrink the size of tumors and lower postoperative complications [106].
Although there is no specific macroscopic feature for primary squamous carcinoma of the
stomach, recently Oono et al demonstrated a well demarcated, white superficial depressed
area of primary squamous carcinoma as an early lesion which is not stained by 3.0% lugol
solution on chromoendoscopy [107]. Main differential diagnosis of primary squamous
carcinoma of the stomach is primary squamous carcinoma of the esophagus that involves the
proximal stomach. Parks et al have proposed the diagnostic criteria for primary squamous
carcinoma of the stomach based on not only histologically definite squamous features but also
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in regard to clinical findings as follows: (1) the tumor must not be located in the cardia; (2) the
tumor must not extend into the esophagus; (3) there should be no evidence of squamous
carcinoma in any other part of the body [108] (Fig.10). Another criteria for primary squamous
carcinoma of the stomach by the Japanese Classification of Gastric Carcinoma are as follows:
(1) the tumor must consist of only squamous carcinoma without any component of adenocar‐
cinoma (pure squamous component only) (Fig.11) and (2) any tumor near esophagogastric
junction must be excluded unless evidence for supporting the tumor originated from the
stomach exists [109].
The origin of primary squamous carcinoma of the stomach is unclear, but four hypotheses
concerning its development have been proposed, including (1) nests of ectopic squamous cells
in gastric mucosa; (2) squamous metaplasia of the gastric mucosa before malignant transfor‐
mation; (3) squamous differentiation in a preexisting adenocarcinoma; and (4) multipotential
stem cells in the gastric mucosa [110-112].
Focal squamous differentiation in the intestinal-type adenocarcinoma is relatively common.
Therefore, Straus et al established a diagnostic criteria for adenosquamous carcinoma of the
stomach that the squamous component should be present in more than 25 percent of the
resected tumor (Fig.12 and 13) [111]. Its biological behavior is usually determined by the
adenocarcinoma component. Also the diagnostic criteria by Parks should be applied for the
final diagnosis of primary gastric adenosquamous carcinoma to exclude primary esophageal
cancer and metastatic lesion.
Figure 10. Gross photograph of pure squamous carcinoma. Gastrectomy specimen displays a large, fungating solid
mass with surface ulceration and necrosis.
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Figure 11. A. Dense solid sheets of squamous carcinoma invade into the submucosa. B. At high magnification, infil‐
trating solid nests of tumor cells show marked pleomorphism, intercellular bridges, and high mitotic counts.
Figure 12. Gross photograph of adenosquamous carcinoma. Adenosquamous carcinoma with a pale yellow solid cut
surface that involves all the gastric wall and an attached lymph node.
Differential diagnosis of primary squamous and adenosquamous carcinoma of the stomach
include (1) gastric adenocarcinoma, intestinal type, with squamous differentiation; (2) chronic
gastritis or ulcer with squamous metaplasia; (3) esophageal squamous carcinoma arising from
the esophagogastric junction; (4) metastatic squamous carcinoma to the stomach. Most of
reported cases of primary squamous and adenosquamous carcinoma of the stomach have
demonstrated a poorer clinical course and prognosis than conventional gastric adenocarcino‐
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ma. The mean survival after surgery is less than 12 months (1-16 months) [113]. Radical surgical
excision is the only option for localized disease. For advanced-stage disease, surgery plus
adjuvant radio-and/or chemotherapy appears to achieve a better outcome than surgery alone
in terms of longer survival, although experience is limited due to the rarity of this variant.
Figure 13. A. A mixed area of both glandular and squamous carcinoma. B. At high magnification, a mixed area of
squamous carcinoma with prominent keratin formation and adjacent adenocarcinoma with intraluminal abscess is
seen.
6. Choriocarcinoma
Primary choriocarcinoma of the stomach (PCCS) is a highly aggressive variant of gastric
carcinoma that was described for the first time by Davidsohn in 1905 [114]. This variant
represents approximately 0.08 % of all the gastric cancers [115]. Pure gastric choriocarcinomas
are extremely rare and only less than twenty cases were reported [116-118]. Most of primary
gastric choriocarcinomas have been reported as a composite or mixed tumor with a combina‐
tion of predominant choriocarcinoma component and a variable degree of adenocarcinoma.
Transitions between adenocarcinoma and choriocarcinoma component may be clear or not.
Yolk sac tumor, small cell carcinoma, and hepatoid carcinoma components may be seen as
well [119-122]. In the study by Kobayashi et al, the average age of the patients with PCCS is
62.4 years in men and 54.8 years in women with a male predominance (male: female ratio=2.3:1)
[123]. The clinical presentation of this variant is similar to that of gastric adenocarcinoma,
however, it is a frequent cause of gastrointestinal bleeding and may have some hormonal
effects such as gynecomastia in men, precocious puberty, pregnancy mimicking symptoms
including amenorrhea, nausea and vomiting in women [124, 125].
PCCS behaves more like gestational choriocarcinoma because it shows extensive hematoge‐
nous dissemination or metastasis by mixed or pure components of choriocarcinoma as
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opposed to the routine lymphatic spreading of gastric adenocarcinoma. Kobayashi et al
analyzed previously reported 53 cases of PCCS and concluded that the most common cause
of death in patients with PCCS is hepatic failure caused by liver metastasis followed by massive
cancerous hemorrhage [123]. Untreated patients with PCCS have an average survival of several
months [126]. Although no standard therapy has been established, complete surgical resection
with neoadjuvant chemotherapy for non-gestational choriocarcinoma has been used in most
of cases. Noguchi et al have reported a good response with the combination chemotherapy of
5-fluouracil and cisplatin after surgery [127]. However, radiotherapy did not show any
improvement for clinical course and outcome [126]. Basically, accurate diagnosis by initial
biopsy, curative resection, early and appropriate intervention by chemotherapy, and the
absence of combined liver metastasis are favorable prognostic factors for patients with PCCS.
The significance of an elevated serum β-human chorionic gonadotropin (HCG) is controver‐
sial. Some studies suggested that it is associated with a shorten survival and poorer prognosis
[128]. However, other insisted that it does not have any prognostic significance [129]. β-HCG
can be detected in blood or tissue in about 10% of patients with conventional gastric carcinoma;
however, many of these tumors do not show any histologic evidence of the presence of
choriocarcinoma component [130-132]. Also, the elevation of serum β-HCG and HCG immu‐
noreactivity on tissue in these patients were usually mild. Most of reported cases of PCCS have
been accompanied by markedly elevated serum level of β-HCG level up to 53,000 IU/ml at the
presentation preoperatively and it significantly declined to the low level or baseline several
months after surgeries. So, monitoring serum β-HCG level may have a role in evaluating
response to treatment and tumor recurrence.
Macroscopically, this tumor usually occurs as a large exophytic mass with extensive necrosis and
hemorrhage. Radiographically, it is a heterogeneous mass with enhanced vascularity and
hemorrhage, mimicking a vascular tumor such as cavernous hemangioma [133]. Microscopical‐
ly, this variant consists of choriocarcinoma and conventional adenocarcinoma with a variable
proportion. Choriocarcinoma exhibits a typical biphasic pattern of admixed cytotrophoblasts
and syncytiotrophoblasts.  Polygonal cytotrophoblasts are located with a central core and
surrounded by a peripheral rim of multinucleated syncytiotrophoblasts. Cytotrophoblasts have
large, round hyperchromatic nuclei, abnormal nuclear chromatin, irregular nuclear mem‐
branes, occasional prominent nucleoli,  and dense eosinophilic to amphophilic cytoplasm.
Pleomorphic and multinucleated large cells are syncytiotrophoblasts. The viable tumor cells are
found mainly at the lesion’s periphery while extensive hemorrhage and necrosis are often in the
center of the tumor like gestational choriocarcinoma. Typical and atypical mitotic figures may
be frequently found. This tumor can show vascular invasion with tumor thrombi and tumor cells
lining vascular spaces occasionally. Adenocarcinoma components would be tubular or papil‐
lary type with varying degree of differentiation. This tumor has been frequently misdiagnosed
as gastric adenocarcinoma at presentation due to the size of tumor, massive tumor necrosis, and
combined adenocarcinoma element. The diagnosis may even more become difficult in a small
gastric biopsy from the lesion because it may reveal only scant syncytiotrophoblasts inter‐
mixed with recognizable routine adenocarcinoma component. Only 8% of PCCS cases in a pooled
analysis of 53 cases were correctly diagnosed as choriocarcinoma in an initial biopsy [123].
Therefore. an extensive and large tissue sampling would be required for a precise diagnosis of
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PCCS prior to surgery. In addition, if the biopsy contain any suspicious elements that suggest
syncytiotrophoblasts,  immunohistochemical  biomarkers  for  trophoblastic  cells  will  help
confirming the diagnosis. In most instances, choriocarcinomatous cells are strongly positive for
cytokeratin, β-HCG, and weakly positive for human placental lactogen. However, PCCS may
not express β-HCG in the tumor tissue by immunohistochemistry [134].
Regarding the pathogenesis of PCCS, several theories have been proposed. The dedifferen‐
tiation theory first proposed by Pick in 1926 has been the most accepted explanation for the
pathogenesis of choriocarcinoma [135]. Liu et al reported the first interphase cytogenetic study
of PCCS, the results of which support this theory that PCCS arises from an alternative
differentiation pathway, a dedifferentiation, of primary gastric adenocarcinoma [135, 136]. In
this study, PCCSs showed the gain of chromosome 12, which is frequently associated with
choriocarcinoma, and other genomic imbalances (gains of function mutations in 2q, 7pq, 8pq,
13q, 17q, 18q, 20pq and deletions in 17p) that are common genomic mutations in conventional
gastric adenocarcinoma.
The major differential diagnosis of PCCS is metastatic trophoblastic tumor from other sites,
particularly a non-gestational gonadal or extragonadal germ cell tumor from men and intrauter‐
ine or extrauterine gestational trophoblastic tumor in reproductive aged women. Extensive
radiologic and clinical evaluation is recommended to rule out metastatic trophoblastic tumor
from genital tracts in the men and women to make an unequivocal PCCS diagnosis.
7. Sarcomatoid carcinoma
Since Queckenstedt described the existence of the sarcomatous component in the gastric
adenocarcinoma in 1904, approximately 50 cases of gastric sarcomatoid carcinoma have been
reported [137]. Sarcomatoid carcinoma of the stomach (SCS) - also referred to as carcinosar‐
coma, malignant mixed mesodermal tumor, spindle cell carcinoma, and pseudosarcoma- is an
uncommon variant of gastric carcinoma which is a biphasic neoplasm composed of a mixture
of malignant epithelial and mesenchymal components. The various terms in use represent the
uncertain histogenesis of this tumor, whether sarcomatoid carcinomas represent a single or
two separate entities (carcinoma with sarcomatoid differentiation versus collision tumor
consisting of carcinoma and sarcoma) remains controversial; however, some stromal tumor
cells of SCS showing epithelial features such as staining for cytokeratin favor a monoclonal
origin with divergent transformation.
The mean age of presentation is 45 years (range, 27 to 74 years) and males are predominantly
affected (2.3:1), with patients frequently having metastasis to regional lymph nodes and liver
at the time of diagnosis [138, 139]. Due to this tumor detecting at advance stage and its rapid
growth, most of SCSs are associated with a poor clinical outcome. Sato et al reported a mean
survival of 10 months in patients with SCS [140]. The current standard therapy for SCS is partial
or total gastrectomy with regional lymph node dissection. The effects of chemotherapy or
radiotherapy have not been established [141]. SCS may present synchrononously with
conventional adenocarcinoma. However, there is no case of SCS that develops secondarily in
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patients with prior chemotherapy, which is different from primary sarcomatoid carcinoma
arising from other organs. SCS usually occurs in the antral or pyloric region and infiltrates the
gastric wall frequently. Macroscopically, it is a polypoid, exophytic, or endophytic mass with
ulceration (Fig.14) [139, 140, 142-146]. Histologically, SCS exhibits an adenocarcinoma
component with variable differentiation and a high-grade sarcomatous component composed
of spindle cells with high cellularity, frequent mitotic counts with atypical forms and pleo‐
morphism (Fig.15). The spindle cells generally have plump, pleomorphic nuclei with a coarsely
stippled chromatin pattern and small nucleoli with a haphazard arrangement. The transition
between epithelial and sarcomatoid components can be abrupt but two components may
intermix with each other. The epithelial component is predominantly composed of adenocar‐
cinoma but rarely adenosquamous and neuroendocrine cell carcinoma can be accompanied
[82, 83, 140]. Some cases represent atrophic gastritis and dysplasia in the background gastric
epithelium [142, 145].
Figure 14. Gross and microscopic photographs of sarcomatoid carcinoma. A. This variant frequently appears as a poly‐
poid or exophytic mass in the antrum. B. Low-magnification view shows a relatively well circumscribed dense mass.
The proportion of the sarcomatoid component is highly variable (5 % up to 80 %) [83, 139,
147]. In most instances, the pattern typically resembles that seen in high grade spindle
sarcomas which lack specific immunohistochemical markers for identifying the line of
differentiation [83, 84, 141, 148]. In some cases, the sarcomatous component can be heterolo‐
gous, with osteosarcomatous, chondrosarcomatous, and rhabdomyosarcomatous or leiomyo‐
sarcomatous differentiation [82, 139, 146, 149, 150]. There have been three cases reported
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showing multidirectional differentiation including rhabdomyosarcoma, osteosarcoma, and
chondrosarcoma [139, 147, 148].
Figure 15. Microscopic photographs of sarcomatoid carcinoma. A. Adenocarcinoma component is entrapped by sar‐
comatoid cell component. B. At high magnification, the glandular component showing anastomosing or cribriform
pattern is surrounded by dense spindle cells. The spindle cells show compact and hyperchromatic nuclei with marked
pleomorphism. This biphasic pattern supports the diagnosis of this variant. The sarcomatous component may display
heterologous differentiation toward skeletal and smooth muscle, bone, and cartilage.
The epithelial component is identified by CK, EMA, or Cam 5.2, whereas muscle markers
like desmin, myogenin, or myoD1 may confirm rhabdomyoblastic differentiation and when
chondrosarcoma  or  liposarcoma  is  suspected,  S100  protein  can  be  used  to  confirm  the
diagnosis.  In  rare  cases  such  as  the  epithelial  component  containing  neuroendocrine
differentiation, neuroendocrine markers (synaptophysin, chromogranin, and CD56) would
be useful.
Differential diagnoses of SCS include other primary gastric sarcomas. If primary gastric
sarcoma is suspected based on radiologic and endoscopic findings, multiple and extensive
sampling of the lesion should be performed to avoid missing an epithelial component. Another
consideration is the extremely rare instance of osseous metaplasia arising in the conventional
gastric adenocarcinoma. Unusual bone component in the stomach can be mistaken for a part
of SCS element. However, the bone component is histologically benign [151, 152]. Similarly,
differentiating SCS from benign, borderline, and malignant spindle cell tumors, such as
inflammatory fibroid polyp, calcifying fibrous tumor, gastrointestinal stromal tumor, and
plexiform angiomyxoid myofibroblastic tumor need to be considered.
8. Acinar cell carcinoma
Acinar cell carcinoma of the stomach (ACCS) defined to have immunohistochemical evidence
of pancreatic exocrine enzyme production, is an uncommon variant of gastric adenocarcinoma
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that is morphologically resemble to primary pancreatic acinar cell carcinoma. Pure ACCS is
extremely rare and only two cases had been reported [153, 154]. Most of reported ACCS are
mixed tumors which combine with glandular and/or neuroendocrine carcinoma components.
Microscopically, this variant demonstrates acinar, solid, glandular/microglandular, and
trabecular arrangement of cells forming large, densely cellular tumor nodules containing
minimal stroma (Fig.16). Tumor cells forming acini are cuboidal or columnar cells similar to
size of normal pancreatic acinar cells with basally located nuclei and apical eosinophilic
granular cytoplasm (Fig 17). Nuclei are round to oval, with minimal to mild pleomorphism,
indistinct nucleoli or occasional single nucleolus. Mitotic activity is variable. The cytoplasm is
moderately abundant, eosinophilic, and granular. The non-neoplastic stomach shows chronic
gastritis with intestinal metaplasia. ACCS can exhibit different morphologic features such as
focal ductal differentiation and well-formed individual ductal elements with mucin produc‐
tion that are uncommon in primary acinar cell carcinoma of the pancreas [155]. Periodic acid-
Schiff reaction after diastase digestion and Grimelius stains demonstrate characteristic positive
granules within the cytoplasm of the tumor cells. By immunohistochemistry, the tumor cells
express pancreatic exocrine enzymes, predominantly trypsin, and variably lipase, α-1 anti-
trypsin, α-1 anti-chymotrypsin and chymotrypsin. Among many pancreatic enzymes, trypsin
is one of the most common and useful markers for the diagnosis of ACCS. The frequency of
trypsin expression in series varied from 71% to 100% (average, 97%), whereas chymotrypsin
expression ranged from 39% to 100% (average, 66%) [156]. The antigens α-1 antitrypsin and
α-1 chymotrypsin can be positive for some tumor cells but not specific for ACCS [153, 157].
Another important diagnostic feature of acinar cell carcinoma is the presence of zymogen
granules, which are large (250 to 1000 μm) electron-dense, homogeneous granules on electron
microscopy [155].
Figure 16. Microscopic photographs of acinar cell carcinoma. A. This variant shows trabecular and glandular arrange‐
ment of tumor cells. B. High magnification view demonstrates solid sheets of cuboidal cells with moderate pleomor‐
phism and eosinophilic granular cytoplasm. Occasional mitoses and giant tumor cells are seen.
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The histogenesis of ACCS is unclear.  There are several hypotheses that may explain the
origin  of  this  variant.  Because  pancreatic  heterotopia  is  relatively  common in  the  stom‐
ach, origin in heterotopic pancreatic tissue was proposed first. Some ACCSs arising from
heterotopic  pancreas have been reported [158-163].  Acinar cell  metaplasia  is  a  relatively
common finding in the gastric mucosa, either as a congenital abnormality, or in associa‐
tion  with  chronic  gastritis  [164-167].  ACCS  may  arise  from  this  metaplastic  process.
Ambrosini-Spaltro et al reported an ACCS arising in association with pancreatic metapla‐
sia in the gastric mucosa [168]. The possibility of the presence of “pluripotent stem cells”
in the gastric mucosa, which have the potential to grow and differentiate to diverse cell
types and neoplasms has been suggested by several studies of gastric composite tumors by
morphology,  ultrastructural  examination,  immunohistochemistry,  and molecular  genetics
[157, 169, 170]. Fukunaga reported a gastric carcinoma resembling pancreatic mixed acinar-
neuroendocrine carcinoma and proposed the possibility of a primitive multipotent cell with
the capacity of divergent differentiation to explain acinar and neuroendocrine differentia‐
tion in the tumor [157].
The main differential diagnosis is metastatic lesion from pancreatic neoplasm. Since immu‐
nohistochemical expression of this tumor in the stomach and pancreas is exactly same, full
clinical and radiographic evaluation would be essential to exclude the possibility of metastasis
from pancreas.
The prognosis of primary ACCS is unknown due to the scarcity of reported cases. However,
considering 50% of patients with primary pancreatic acinar cell carcinoma having metastases
at presentation and a worse prognosis, the recognition of acinar cell component in gastric
carcinoma may be important for the patients’ treatment and prognosis.
Figure 17. A and B. Microscopic photographs of acinar cell carcinoma. This tumor shows a prominent acinar growth
pattern mimicking normal pancreatic acinar cells with prominent ductal elements with mucin.
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9. Invasive micropapillary carcinoma
Recently, an unusual variant of gastric adenocarcinoma called “ invasive micropapillary
carcinoma of the stomach (IMPCS)” has been described by Shimoda et al in 2008 [171]. In a
recent study by Roh et al, IMPCSs were present in up to 0.07% of 1,5254 total or subtotal
gastrectomy specimens [172]. The mean age of this variant is 66.2 years (range 36-87 years)
with a male predominance (male to female ratio: 2.5-3:1). This rare tumor demonstrates an
aggressive behavior associated with a higher incidence of lymphovascular invasion and lymph
node metastasis, resulting in a poor prognosis similar to invasive micropapillary carcinomas
(IMPCs) of other organs including breast, urinary bladder, ureter, lung, parotid gland, and
colon [173-179]. In the reported series to date, patients with IMPCS have an estimated 30% of
5- year overall survival rate compared to those with non-IMPCS having 67% of 5-year survival
by Kaplan-Meir method [172].
Histologically, this variant consists of small tight cell clusters of papillary structure devoid of
fibrovascular cores within lacunar spaces mimicking lymphatic or vascular channels (Fig.18).
The lacunar spaces are artifactual tissue spaces and not lined by an endothelial cell. Several
adjunct markers have been introduced to enhance the recognition of IMPCs. IMPCs in most
organ systems are characterized by inverted polarity with MUC1 expression with membra‐
nous MUC1 staining facing the stroma [180]. Similarly, epithelial membrane antigen shows
reverse polarity expression in IMPCs [181]. However, focal or heterogeneous staining pattern
of IMPCs by MUC1 and EMA can be seen. Other immunohistochemical expressions of KL-6,
CA125, and HER2/neu are frequently increased in IMPCs of the urinary tract but lack of
specificity as an ancillary maker [181-184].
Figure 18. Invasive micropapillary carcinoma. A. Typical pathologic features of micropapillary carcinoma lined by clear
spaces without lining cells nor mucin are seen. Papillary adenocarcinoma within lymphatic space is a lesion mimicking
micropapillary carcinoma. B. In lymphatic spaces, the numbers of papillae are more than two unlike one in micropapil‐
lary carcinoma.
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No“ pure” form of IMPCS has been reported and all cases of IMPCS reported have been
combined with conventional or papillary gastric adenocarcinoma. In the series of 72 IMPCS
cases by Eom et al, most of the combined adenocarcinoma components were characterized as
intestinal type (64/72 cases, 88.9%) and papillary adenocarcinoma (43/72 cases, 59.7%), and the
remaining were classified as diffuse type (8/72 cases, 11.1%) and tubular adenocarcinoma
(21/72 cases, 29.2%) [185].
Although IMPC has become increasingly well recognized as a distinct and aggressive variant
in stomach as well as other organs from recent vigorous studies. Diagnostic criteria for a
diagnosis of IMPCS remain imprecise. In a recent study about interobserver reproducibility
in the diagnosis of IMPC of the urinary tract, this study recommended a combination of some
histologic features included small tumor cell nests within stromal retraction spaces, back-to-
back lacunae, multiple tumor nests within each single retraction space are useful to make a
diagnosis for “classic” IMPC that may bring a better reproducibility. Additional associated
histologic features to be considered including epithelial ring forms, intracytoplasmic vacuoli‐
zation, elongated epithelial nests (i.e., micropapillae), and peripherally oriented nuclei. These
diagnostic criteria of IMPC in the urinary tract based on a combination of several histologic
features would be highly useful to make a diagnosis of IMPCs in other organs including
stomach. In addition, the threshold for a diagnosis of IMPCs based on the percentage/volume
of IMPC component is undetermined. There has been no validated clinicopathologic data that
support the threshold of IMPC proportion in association with a clinical outcome in patients
with IMPC. One study of IMPCs in the urinary tract showed a trend towards an association
between the proportion of IMPC and survival with >50 % IMPC component imparting a
relative mortality risk of 2.4, compared to with < 50% IMPC of those [186]. However, Kim et
al suggested that the proportion of IMPC component with respect the whole tumor is not
related with the prognosis of the patients with IMPC in the colorectum [187]. In the stomach,
Roh et al failed to find any significant clinicopathologic differences between a group with ≤
20% of IMPC component and another group with > 20% of IMPC component [172]. Some
studies suggest an arbitrary cutoff of IMPCS as ≥ 5% of IMPC proportion in total tumor volume
but ≥ 10% of IMPC proportion in other studies [172, 185]. Approximately 70% of reported cases
in the stomach were found that the proportion of IMPC component to the entire tumor ranged
from 10% to 70%. In previous published cases of IMPC of the colorectum, the proportion of
IMPC component ranged from 5 % to 80 % but was usually less than 30 % of the entire lesion
[178, 187, 188]. Comperat et al analyzed 72 cases of IMPC of the urinary bladder and the
proportions of IMPC component are: 10% of cases with less than 10% of IMPC component,
47% of cases with 10%-50% of those, and 43% of cases with more than 50% of these [189].
Further studies are needed to have an established criteria for IMPCS showing a good repro‐
ducibility among inter-and intraobservers and to evaluate a diagnostic threshold of IMPC
proportion in total volume of the tumor that correlate best with the clinical outcome.
The incidence of metastasis of IMPC from other organs to the stomach is uncommon. The
possible metastatic lesions of IMPCs from other organs included urinary bladder, breast, lung,
and ovary. Lotan et al investigated immunohistochemical markers to identify the primary site
and differentiate metastatic lesions of IMPC [190]. They recommended that an immunohisto‐
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chemical panel consisting of uroplakin, CK20, TTF-1, ER and WT-1, and/or PAX8, and
mammaglobin is the best one for accurately classifying the likely primary site of IMPC. In their
studies, urothelial IMPC were usually positive for uroplakin and CK20, whereas p63, high
molecular weight cytokeratin, and thrombomodulin were less sensitive and specific. Lung
IMPC was uniformly TTF-1 positive. Breast IMPC was ER positive, mammaglobin positive,
and PAX8/WT-1 negative, while ovarian IMPC was ER positive, mammaglobin negative, and
PAX/WT-1 positive. However, no specific marker has been introduced for verifying specifi‐
cally IMPCS.
The main differential entity of IMPCS is papillary adenocarcinoma or conventional adenocar‐
cinoma with multiple endolymphatic tumor emboli. Morphologically, when a distinction of
IMPC within lacunar spaces from lymphovascular tumor emboli may be difficult, immuno‐
histochemical studies including factor VIII, Ulex europaeus, CD31, CD34, and D2-40 as well as
FLI1 and Erg nuclear stains would be useful to rule out lymphovascular tumor emboli from
other types of adenocarcinoma (Fig.19) [191].
Figure 19. A. Invasive micropapillary variant showing tight small clusters of papillary structures within lacunar spaces.
B. Immunohistochemical stain for D2-40 would be useful to rule out lymphatic tumor emboli.
10. Gastric adenocarcinoma of fundic gland type (chief cell predominant
type)
Recently, Ueyama et al proposed gastric adenocarcinoma of fundic gland type for a new entity
of gastric carcinoma [192]. Although gastric adenocarcinomas with foveolar and pyloric gland
type differentiation are relatively common, only a few cases of gastric adenocarcinomas with
fundic gland differentiation have been reported. This variant is a well differentiated adeno‐
carcinoma composed of mixed chief and parietal cells mimicking fundic glands (Fig.20). In
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addition to histologic similarity of chief and parietal cells, immunohistochemical staining with
pepsinogen I (a marker for chief cells) and H+/K+ATPase (a marker for parietal cells) exhibit
differentiation toward the chief and parietal cells in gastric adenocarcinoma. In the series by
Ueyama et al and Singhi et al, the patients’ age range from 42 to 79 years (average: 65 years)
with a relatively equal sex distribution [192, 193].
Gastric adenocarcinoma of fundic gland type is a relatively small tumor, the maximum
diameter of tumors range from 0.2 to 2 cm (average 0.6 cm) [192, 193]. Characteristically, gastric
adenocarcinomas of fundic gland type are located in areas with oxyntic mucosa, in the upper
third of the stomach, fundus and cardia [192, 193]. Macroscopic findings of this variant in early
lesion are the superficial depressed type (type 0-IIc) or superficial elevated type (type 0-IIa)
[192]. Histologically, this variant is a well-differentiated adenocarcinoma composed of
columnar cells admixed with predominantly chief cells, with pale grey-blue, basophilic
cytoplasm, and scattered parietal cells, with coarse granular eosinophilic cytoplasm. Both cells
exhibit mildly enlarged and hyperchromatic nuclei with slight pleomorphism. Mitotic activity
is absent or very low.
Differential diagnosis includes fundic gland polyps that are small benign mucosal polyps that
occur in the gastric fundus. Histologically, they are composed of dilated glands lined by
oxyntic mucosa without atypia.
Figure 20. Microscopic photographs of gastric adenocarcinoma of fundic gland type. A. This variant is a well-differen‐
tiated adenocarcinoma mimicking the normal gastric fundic gland with irregular branching and angulated structures
that invades in to the lamina propria. B. This adenocarcinoma predominantly consists of tumor cells mimicking chief
cells with pale basophilic cytoplasm and basally located nuclei and scattered parietal cells with coarse granular eosino‐
philic cytoplasm.
11. Parietal cell carcinoma and oncocytic carcinoma
Since Capella et al originally described in 1984 as “gastric parietal cell carcinoma”, less than
30 cases have been reported to date [194]. The reported mean age of the patients with this
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variant  is  70.2  years  (range  58-84  years)  and  it  exclusively  affects  men  (M:F  ratio=9:1).
Histologically, parietal cell carcinomas are usually composed of solid sheets of polygonal
cells with round nuclei and abundant, finely granular eosinophilic cytoplasm that stain with
phosphotungstic acid-hematoxylin and Luxol Fast Blue [194, 195]. Most of gastric parietal
cell carcinomas are combined with well to moderately differentiated tubular or papillary
adenocarcinoma. Parietal cell differentiation is confirmed by immunoreactivity for antibod‐
ies  specific  for  parietal  cell  biomarkers  H+/K+  ATPase  and  human  milk  fat  globule-2.
Ultrastructurally,  the granular and eosinophilic cytoplasm, so call  “oncocytic cytoplasm”
corresponds to the abundance of mitochondria, intracytoplasmic secretory canaliculi, and
cytoplasmic tubulovesicles [196, 197]. A few previous studies suggested that this variant of
gastric  adenocarcinoma  is  associated  with  a  better  prognosis  than  conventional  gastric
adenocarcinoma  [194,  198-201].  Robey-Cafferty  et  al  reported  a  case  of  parietal  cell
carcinoma with lymphoma-like  morphologic  features  [197].  Takubo et  al  introduced ten
cases  of  oncocytic  adenocarcinoma,  which  are  morphologically  similar  to  parietal  cell
carcinoma but are negative for anti-parietal antibodies [195].
12. Miscellaneous carcinomas
Extremely rare variants of gastric carcinoma have been sporadically reported. Among them
are (1) mucoepidermoid carcinoma of the stomach; one case was reported that this variant
arose from preexisting ectopic mucous glands of stomach [202]. (2) Paneth cell carcinoma or
gastric adenocarcinoma with Paneth cell differentiation; histologically, Paneth cell differen‐
tiation is characterized by cytoplasmic distinct coarse eosinophilic granules stained red with
periodic acid-Schiff and Masson trichrome reagents and reddish brown with phosphotungstic
acid hematoxylin, and electron microscopically by lysozyme in cytoplasmic electron dense
granules [203]. Immunohistochemical staining for lysozyme, human defensin-5, and CDX2 is
usually positive [204, 205]. and (3) gastric carcinoma with osteoclast-like giant cells; these
variants contains a minor component of giant cells that contain 3 to 20 nuclei and are positive
for CD68 and vimentin [206]. These findings suggest that giant cells are of monocytic/
histiocytic origin and probably represent a host response to the tumor [207]. However, the
clinicopathological significance of this variant has not been verified due to its rarity. Salient
features of variants gastric adenocarcinoma are listed in Table 2.
HISTOLOGIC TYPE SALIENT FEATURES OF GASTRIC CANCER VARIANTS
EBV-associated lymphoepithelioma-like
carcinoma
EBV infection related tumor with a dense lymphoid stroma, positive
EBER-ISH, aberrant methylation, and a better prognosis
Hepatoid adenocarcinoma Subtype of AFP producing carcinoma resembling hepatocellular
carcinoma and showing frequent liver metastasis, and a worse
prognosis
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HISTOLOGIC TYPE SALIENT FEATURES OF GASTRIC CANCER VARIANTS
Neuroendocrine cell carcinoma Aggressive tumor with distinct neuroendocrine cell features and a
worse prognosis but good response to chemotherapy
Squamous and adenosquamous
carcinoma
Pure or composite tumors with definite squamous features with a very
strong male predominance and a worse prognosis
Choriocarcinoma Tumors with variable choriocarcinomatous components, elevated β-
HCG in the serum, frequent hematogenous spread and a worse
prognosis
Sarcomatoid carcinoma Biphasic neoplasm composed of a mixture of malignant epithelial and
mesenchymal component with a poor prognosis
Acinar cell carcinoma Adenocarcinoma resembling pancreatic acinar cells with production
of pancreatic exocrine enzyme
Invasive micropapillary carcinoma Adenocarcinoma with micropapillary features showing frequent
lymphovascular invasion and lymph node metastasis
Gastric adenocarcinoma of fundic gland
type (chief cell predominant)
Well differentiated adenocarcinoma mimicking a fundic gland polyp
Parietal cell carcinoma and oncocytic
carcinoma
Well differentiated adenocarcinoma with Parietal cell differentiation
and a better diagnosis
Table 2.
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